ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1627

The Global Antiphospholipid Syndrome Score (GAPSS) Differentiates Between Transient Ischemic Attack and Stroke in Patients with Antiphospholipid Antibodies

Savino Sciascia1, Giovanni Sanna2, Veronica Murru3, Dario Roccatello4, Munther A. Khamashta5 and Maria Laura Bertolaccini3, 112 Kennington Ave, Rayne Institute, St. Thomas Hospital, London, United Kingdom, 2Lupus Unit, St. Thomas' Hospital, London, United Kingdom, 3Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 4CORSO RAFFAELLO 30, UNIVERSITY OF TURIN (ITALY), TURIN, Italy, 5Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Cerebrovascular disease and risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Arterial event are frequent in the antiphospholipid syndrome (APS) and stroke is a major clinical manifestation of syndrome. Recently, we conducted a study in a large cohort of Systemic Lupus Erythematosus (SLE) patients applying a risk score for APS clinical manifestations (Global APS Score or GAPSS), demonstrating that risk profile for APS can be successfully assessed. In this study, we aimed to evaluate the clinical usefulness  of the GAPSS in differentiating between transient ischemic attack (TIA) and stroke in a cohort of patients tested positive for aPL who sufferedcerebrovascular events.

Methods: We included 40 consecutive SLE patients attending the Louise Coote Lupus Unit at St Thomas Hospital, London, all  with a history of cerebravoscular events. Demographic, clinical and laboratory characteristics were collected. aPL profile included anticardiolipin antibodies (aCL), lupus anticoagulant (LA), anti β2 glycoprotein I antibody (anti-β2GPI), and  antibodies to phosphatidylserine-prothrombin complex (aPS/PT). Cardiovascular risk factors were assessed following NICE guidelines (1). The GAPSS system was calculated for each patient (2,3).

Results:

Nineteen  patients (47.5%) had stroke, 16 (40%) a transient ischemic attack (TIA), defined as neurologic symptoms or signs lasting less than 24 hours by a neurologist. Five patients (12.5%) experienced both..  Thirty  patients (75%) fulfilled the current APS classification criteria. Higher values of GAPSS were seen in patients who experienced stroke (alone or in association with TIA) when compared to those with TIA alone (10.13±3.3 [range 5-16] vs. 6.3±4.6 [range 3-13], p=0.033). This observation was confirmed when compared patients who had a history of stroke alone with patients with TIA alone (9.95±3.29 [range 5-16] vs. 6.3±4.6 [range 3-13], p=0.029). Patients who experienced both stroke and TIA showed the highest GAPSS but the difference was only statistically significant when compared to those with TIA alone (10.8±3.63 [range 7-16] vs. 6.3±4.6 [range 3-13], p=0.03).

Conclusion

The GAPSS is a valid tool for risk stratification for ischemic manifestation in the setting of cerebrovascular events.  This tool may help identifying a more “at risk” population in whom a tailored prophylaxis therapy might be beneficial.

References

1. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford). 2013 Aug;52(8):1397-403.

2.Excellence NIfHaC. Hypertension http://publicationsniceorguk/quality-standard-for-hypertension-qs28. 2011.

3. Excellence NIfHaC. Lipid modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. http://guidanceniceorguk/CG/WaveR/123. 2010.


Disclosure:

S. Sciascia,
None;

G. Sanna,
None;

V. Murru,
None;

D. Roccatello,
None;

M. A. Khamashta,
None;

M. L. Bertolaccini,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-global-antiphospholipid-syndrome-score-gapss-differentiates-between-transient-ischemic-attack-and-stroke-in-patients-with-antiphospholipid-antibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology